Cubist Systematic Strategies’s AstraZeneca AZN Stock Holding History

Cubist Systematic Strategies’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,250	Closed	-$729K	–	3496
2023 Q1	$729K	Sell	5,250 -73,050	-93%	-$9.83M	﹤0.01%	2429
2022 Q4	$10.6M	Buy	78,300 +27,750	+55%	+$3.48M	0.06%	442
2022 Q3	$5.54M	Buy	50,550 +44,700	+764%	+$5.67M	0.03%	982
2022 Q2	$773K	Buy	+5,850	New	+$768K	﹤0.01%	2690

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cubist Systematic Strategies's AZN Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its AstraZeneca (AZN) stake by 88% in Q3 2025, selling an estimated $32.3M and leaving 28,594 shares worth $4.39M. The position accounts for 0.02% of the portfolio, ranked #1039.

Cubist Systematic Strategies first reported a position in AZN in Q2 2014 and has held it in 43 quarters since. The position peaked at $33.8M in Q2 2025. 1,288 funds tracked by Wall St. Rank hold AZN as of Q3 2025.

Cubist Systematic Strategies held 28,594 shares of AstraZeneca worth $4.39M as of Q3 2025.
Cubist Systematic Strategies sold 213,445 AstraZeneca shares in Q3 2025, an estimated $32.3M.
AstraZeneca made up 0.02% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1039 holding.
Cubist Systematic Strategies first reported a position in AstraZeneca in Q2 2014 and has held it in 43 quarters since.
Cubist Systematic Strategies's AstraZeneca position peaked at $33.8M in Q2 2025.
1,288 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.